GeoVax Executives Pursue European Partnerships to Advance Vaccine and Cancer Therapy Development
TL;DR
GeoVax executives are meeting with global health organizations and potential partners to secure collaborations that accelerate vaccine development and manufacturing for competitive market positioning.
GeoVax leadership will attend European conferences and conduct structured meetings with NGOs and academic collaborators to advance vaccine development through methodical partnership building.
GeoVax's partnership efforts aim to expand global access to critical vaccines for immunocompromised patients and advance cancer therapies to improve worldwide healthcare outcomes.
GeoVax is showcasing innovative vaccine platforms including Mpox prevention and novel cancer therapies while engaging with global health leaders across multiple European cities.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs senior leadership will participate in key European meetings over the coming weeks to advance partnering discussions for the company's vaccine and immunotherapy portfolio. Chairman and CEO David A. Dodd and Vice President John Sharkey, along with other senior team members, will attend the World Vaccine Congress Europe in Amsterdam from October 14-16 and BIO-Europe Fall in Vienna from November 3-5.
The company plans additional meetings with global non-governmental organizations including WHO, UNICEF, CEPI, Gavi, and the Africa CDC, as well as academic institutional collaborators across Europe. These engagements aim to establish relationships that can accelerate development and expand access to critical vaccines and immunotherapies.
David A. Dodd emphasized the strategic importance of these meetings, stating the company is focused on solidifying durable relationships to support expanded access to critical vaccines and immunotherapies. The engagement priorities include mpox and smallpox preparedness, addressing unmet needs of immunocompromised patients relative to COVID-19, expanding development of Gedeptin® as neoadjuvant cancer therapy, and exploring complementary collaborations across the company's broader platform.
GeoVax will highlight several key programs during these meetings. The GEO-MVA mpox and smallpox vaccine candidate represents a U.S.-based MVA program designed to accelerate access to a second-source vaccine with rapid, scalable manufacturing capabilities. The GEO-CM04S1 multi-antigen COVID-19 vaccine, designed to elicit robust T-cell and antibody responses, focuses on addressing the current unmet needs of an estimated over 400 million immunocompromised patients worldwide.
Gedeptin®, a tumor-targeted immuno-oncology approach, shows potential combination synergies with checkpoint inhibitors and could provide a new neoadjuvant therapy against solid tumors. The company will also discuss broader MVA platform applications including hemorrhagic fever and Zika programs, continuous cell-line manufacturing, and potential technology-transfer collaborations.
Dr. John Sharkey noted that GeoVax continues to receive compelling interest from governments, NGOs, and potential industry collaborators seeking diversified, resilient vaccine supply and clinically differentiated immunotherapies. The company's goal is to convert this interest into structured collaborations that accelerate development, manufacturing readiness, and regional availability.
Additional information about GeoVax and its programs is available at https://www.geovax.com. The original release can be viewed on https://www.newmediawire.com.
Curated from NewMediaWire
